@article {Shishehbor37, author = {Mehdi H. Shishehbor and Stanley L. Hazen}, title = {JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?}, volume = {76}, number = {1}, pages = {37--44}, year = {2009}, doi = {10.3949/ccjm.75a.08105}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) (N Engl J Med 2008; 359:2195{\textendash}2207) compared rosuvastatin (Crestor) 20 mg daily vs placebo in apparently healthy people who had levels of low-density lipoprotein cholesterol (LDL-C) lower than 130 mg/dL but elevated levels (>= 2 mg/L) of high-sensitivity C-reactive protein (hs-CRP). Rosuvastatin treatment lowered LDL-C levels by 50\% and hs-CRP levels by 37\%, accompanied by a 44\% relative risk reduction in the composite end point of unstable angina, revascularization, and confirmed death from cardiovascular causes. In absolute terms, 95 people had to be treated over 2 years to prevent one event. There was, however, a higher incidence of diabetes in the rosuvastatin group.}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/76/1/37}, eprint = {https://www.ccjm.org/content/76/1/37.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }